Allergy and Airway |

Comparision Between Treatment Persistence With Omalizumab in Severe Allergic Asthma and Subcutaneous Immunotherapy in Severe Allergic Rhinitis FREE TO VIEW

Zeynep Ozseker, MD; Ismet Bulut, MD; Derya Erdogdu, MD; Asli Gelincik, MD; Fusun Erdenen, MD; Ramazan Ersoy, MD; Ali Kutlu, MD; Fahrettin Talay, MD; Bahattin Colakoglu, MD; Suna Buyukozturk, MD
Author and Funding Information

Sureyyapasa Chest Diseases and Chest Surgery Training Hospital, Istanbul, Turkey

Chest. 2013;144(4_MeetingAbstracts):77A. doi:10.1378/chest.1703095
Text Size: A A A
Published online


SESSION TITLE: Asthma Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: Long-term treatment regimens in chronic diseases are supposed to decrease patients’ compliance and persistence. Omalizumab is considered at the fifth stage of asthma therapy in severe allergic asthmatic (SAA) patients. Similarly allergen specific immunotherapy (SCIT) is usually added to the pharmacologic treatment in severe allergic rhinitis (SAR). Our aim was to determine the persistence with omalizumab in SAA patients by comparing to the persistence with SCIT in SAR patients.

METHODS: 142 SAA patients and 98 SAR patients who have been receiving omalizumab and SCIT respectively at least for 1 year were included. Demographic features, monthly income of the patients, the cost of transportation to the hospital and the persistence of the treatments were assessed. Asthma control test scores and FEV1 values at the beginning and at the end of treatment were evaluated. The number of attacks, hospitalizations, and the need for systemic corticosteroids were questioned. Rhinitis symptom and visual analog scale (VAS) scores were obtained in SAR patients at the beginning and first year of SCIT.

RESULTS: The mean age of SAA and SAR patients were 46.5±12.2 years (F/M:105/37) and 31.6±10.5 years (F/M: 56/42) respectively. 20 (14.1%) SAA patients and 15 (15.3%) SAR patients discontinued their treatment because of various reasons. The persistence with both treatments was not statistically different (85.9%, 84.7%, respectively p=0.793). The monthly income was higher in SAR group; however the cost of transportation to the hospital was higher in SAA group. In the SAA group, the ACT scores and FEV1 values increased after treatment (p<0.001). The number of attacks, hospitalizations and the need for systemic steroids were significantly decreased in the SAA group (p<0.05 for each). Rhinitis symptom and VAS scores were improved in SAR subjects (p=0.001)

CONCLUSIONS: The persistence with both treatments was found equally high. This finding may be due to the effectiveness of both treatments.

CLINICAL IMPLICATIONS: This study shows that omalizumab has a high rate of treatment persistence among asthma patients despite the necessity to attend to the hospital regularly and a significant cost of transportation.

DISCLOSURE: The following authors have nothing to disclose: Zeynep Ozseker, Ismet Bulut, Derya Erdogdu, Asli Gelincik, Fusun Erdenen, Ramazan Ersoy, Ali Kutlu, Fahrettin Talay, Bahattin Colakoglu, Suna Buyukozturk

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Omalizumab: not only for asthma. Recent Pat Inflamm Allergy Drug Discov 2008;2(3):191-201.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543